Bradley Harrison
Medical Oncology · Chattanooga, TNNPI 1821520453
Payments from drug & device makers
Across 84 payments — averaging $67.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Daiichi Sankyo Inc.$677
- Incyte Corporation$245
- Regeneron Healthcare Solutions, Inc.$221
- Novartis$206
- GT Medical Technologies, Inc$188
- plus $2K from 30 others
What the payments were for
- Consulting fees$2,90051%
- Food & beverage$2,59546%
- Education$2004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $2,430 |
| Daiichi Sankyo Inc. | 2 | $677 |
| Incyte Corporation | 3 | $245 |
| Regeneron Healthcare Solutions, Inc. | 4 | $221 |
| Novartis | 10 | $206 |
| GT Medical Technologies, Inc | 1 | $188 |
| Eisai Inc. | 3 | $182 |
| Gilead(2 entities) | 3 | $162 |
| AbbVie | 2 | $144 |
| Seagen Inc. | 1 | $100 |
| Merck | 3 | $91 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| Astellas Pharma US Inc | 4 | $86 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $76 |
| Exelixis Inc. | 2 | $73 |
| Johnson & Johnson | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $67 |
| GSK | 3 | $60 |
| Pfizer | 3 | $58 |
| Foundation Medicine, Inc. | 1 | $48 |
| AVEO Pharmaceuticals, Inc. | 1 | $45 |
| Pharmaessentia USA Corporation | 2 | $43 |
| Bristol Myers Squibb | 2 | $39 |
| Legend Biotech USA Inc. | 1 | $37 |
| Genentech USA, Inc. | 1 | $32 |
| Beone Medicines USA, Inc. | 1 | $28 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $22 |
| Fennec Pharmaceuticals, Inc. | 1 | $22 |
| Array Biopharma Inc | 1 | $20 |
| Bayer | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,695 in reported general payments places this provider in the 35th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 17 | $220,406 |
| XtandiEnzalutamide | 15 | $202,202 |
| Neulasta OnproPegfilgrastim | 19 | $107,006 |
| Abiraterone Acetate | 16 | $35,464 |
| Ondansetron Hcl | 52 | $4,251 |
| Prochlorperazine Maleate | 59 | $1,751 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 48 | $912 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $697 |
| Anastrozole | 19 | $644 |
| Ondansetron OdtOndansetron | 27 | $587 |
| Olanzapine | 46 | $549 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 38 | $449 |
| Oxycodone Hcl | 22 | $415 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $374 |
| Dexamethasone | 12 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $19 | $220,40617 claims |
| Astellas Pharma US IncXtandi | $86 | $202,20215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Chattanooga
- Harsha VardhanaChattanooga$40K
- Larry SchlabachChattanooga$22K
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Gregory VidalGermantown$12.5M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Daniel VaenaGermantown$5M
- Ari VanderwaldeGermantown$4.9M
- Gina VaccaroCookeville$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.